SKP2 and colorectal carcinoma: Having determined that SKP2 copy number losses occur in 10.8% of CRC patients and that reduced expression corresponds with CIN, which is proposed to be an early driver of CRC development, we next sought to develop clinically relevant heterozygous and homozygous models in which CIN could be assessed over time.